Related Experiment Videos
HLA class I defects in malignant lesions: what have we learned?
Chien-Chung Chang1, Michael Campoli, Soldano Ferrone
1Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
The Keio Journal of Medicine
|January 30, 2004
Summary
Human Leukocyte Antigen (HLA) class I antigen loss is common in cancers, correlating with poor prognosis. This immune escape mechanism hinders T cell therapy effectiveness, necessitating monitoring and new strategies.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Downregulation or loss of Human Leukocyte Antigen (HLA) class I antigens is observed in 16-50% of malignant lesions across various cancers.
- This phenomenon is clinically associated with poor prognosis, reduced disease-free interval, and decreased patient survival.
Purpose of the Study:
- To investigate the mechanisms underlying HLA class I antigen abnormalities in malignant cells.
- To understand how these abnormalities contribute to tumor cell immune evasion.
- To explore the role of immunoselection in the development of HLA class I defects.
Main Methods:
- Characterization of molecular defects affecting HLA class I antigen expression.
- Analysis of gene structure and antigen processing machinery components.
- Evaluation of clinical recurrence data following T cell-based immunotherapy.
Main Results:
- Identified diverse molecular defects, including structural gene alterations and deregulation of antigen processing machinery.
- Demonstrated a link between HLA class I abnormalities and tumor cell escape from cytotoxic T lymphocytes.
- Observed clinical recurrence of lesions with HLA class I loss after T cell immunotherapy, suggesting immunoselection.
Conclusions:
- Molecular defects in HLA class I antigen expression are common in malignancies and facilitate immune evasion.
- Immunoselection likely plays a role in generating malignant lesions with HLA class I abnormalities.
- Effective monitoring of functional HLA class I expression and development of strategies to overcome immunoselection are crucial for T cell-based immunotherapy.